Aa-Z2 triggers ROS-induced apoptosis of osteosarcoma by targeting PDK-1

Background Osteosarcoma (OS) is the most frequent cancer derived from bone, and the prognosis of OS is poor. Metabolic alterations have been previously reported to contribute to the development of OS, and arsenic compounds have been suggested to exhibit strong anti-OS effects. However, few studies have described the therapeutic efficiency of arsenic compounds by targeting metabolism in OS.Methods Here, we presented a novel organo-arsenic compound, Aa-Z2, and its antitumour efficacy against OS both in vitro and in vivo.Results Aa-Z2 induced OS cell apoptosis, G2/M phase arrest, and autophagy through the accumulation of reactive oxygen species (ROS). Elevated ROS functioned by promoting the mitochondrial-dependent caspase cascade and attenuating the PI3K/Akt/mTOR signalling pathway. N-acetylcysteine (NAC), a kind of ROS scavenger, could reverse the effects of Aa-Z2 treatment on 143B and HOS cells. Specifically, by targeting pyruvate dehydrogenase kinase 1 (PDK-1), Aa-Z2 induced changes in mitochondrial membrane potential and alterations in glucose metabolism to accumulate ROS. Overexpression of PDK-1 could partially desensitize OS cells to Aa-Z2 treatment. Importantly, Aa-Z2 suppressed tumour growth in our xenograft osteosarcoma model.Conclusion The study provides new insights into the mechanism of Aa-Z2-related metabolic alterations in OS inhibition, as well as pharmacologic evidence supporting the development of metabolism-targeting therapeutics.

Automated summary

This study investigates the therapeutic efficiency of a novel organo-arsenic compound Aa-Z2 targeting metabolism in osteosarcoma. Aa-Z2 induces apoptosis, G2/M phase arrest, and autophagy in osteosarcoma cells through the accumulation of reactive oxygen species (ROS). Furthermore, Aa-Z2 alters mitochondrial membrane potential and glucose metabolism by targeting pyruvate dehydrogenase kinase 1 (PDK-1) to accumulate ROS. Overall, this study reveals the mechanism of Aa-Z2-related metabolic alterations in osteosarcoma inhibition and provides pharmacologic evidence for the development of metabolism-targeting therapeutics.